Created at	Source	Raw Value	Validated value
Nov. 26, 2021, 10:30 p.m.	oms	1.Pregnant and lactating women <br/ >2.Patients on CYP3A4 inhibitors and P- glycoprotein inhibitors <br/ >3.Patients with known blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia and aplastic anemia <br/ >4.Patients with Hepatitis B, ,Hep.C positive status and liver disorders <br/ >	1.Pregnant and lactating women <br/ >2.Patients on CYP3A4 inhibitors and P- glycoprotein inhibitors <br/ >3.Patients with known blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia and aplastic anemia <br/ >4.Patients with Hepatitis B, ,Hep.C positive status and liver disorders <br/ >
Nov. 13, 2021, 5:33 p.m.	oms	N/A	N/A
Dec. 16, 2020, 10:47 a.m.	oms	1.Pregnant and lactating women <br/ >2.Patients on CYP3A4 inhibitors and P- glycoprotein inhibitors <br/ >3.Patients with known blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia and aplastic anemia <br/ >4.Patients with Hepatitis B, ,Hep.C positive status and liver disorders <br/ >	1.Pregnant and lactating women <br/ >2.Patients on CYP3A4 inhibitors and P- glycoprotein inhibitors <br/ >3.Patients with known blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia and aplastic anemia <br/ >4.Patients with Hepatitis B, ,Hep.C positive status and liver disorders <br/ >